Chronic Kidney Disease, Kidney Failure, Left Ventricular Hypertrophy, Hemodialysis research hub

SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL

This study looks at a medicine called dapagliflozin (Forxiga) for people on dialysis with kidney problems, both with and without diabetes. We want to see if it helps reduce a common heart issue called Left Ventricular Hypertrophy, which is when the heart muscle thickens.